To examine the effects of nifedipine
GITS on clinical outcome in patients with concurrent stable angina and hypertension.
Data from the double-blind placebo-controlled ACTION trial was stratified for hypertension (blood pressure ≥ 140/90 mmHg), at baseline.
A total of 52% of 7665 ACTION patients were hypertensive. Some 80% were on a β blocker; hypertensives were more often treated with other blood pressure-lowering drugs. Mean baseline blood pressure was 122/74 mmHg among normotensives and 151/85 mmHg among hypertensives. Follow-up blood pressures were reduced by nifedipine
< 0.001) on the average by 3.9/2.4 and 6.6/3.5 mmHg among normotensives and hypertensives, respectively. Nifedipine
GITS significantly (P
< 0.05) reduced the combined incidence of all-cause mortality, myocardial infarction, refractory angina, heart failure, stroke and peripheral revascularization by 13% in hypertensives only. Nifedipine
significantly reduced the incidence of any stroke or transient ischemic attack by almost 30% in both subgroups and the need for coronary angiography by 21% in normotensives and 16% in hypertensives. Among hypertensives, the incidence of new overt heart failure was significantly reduced by 38% and of debilitating stroke by 33%. Among normotensives, the need for coronary bypass grafting was significantly reduced by 32%. Nifedipine
did not affect all-cause death, cardiovascular death and myocardial infarction in either normo- or hypertensives, but increased the need for peripheral revascularization.
The salutary effects of the addition of nifedipine
GITS to the basic regimen of patients with concurrent stable symptomatic coronary artery disease
and hypertension emphasize the need for blood pressure control.